Dapirolizumab pegol

Dapirolizumab pegol is "a polyethylene glycol conjugated anti-CD40L Fab fragment" developed by Biogen for systemic lupus erythematosus.^[1]^[2]^[3]

References

^ Chamberlain, Chris; Colman, Peter J; Ranger, Ann M; Burkly, Linda C; Johnston, Geoffrey I; Otoul, Christian; Stach, Christian; Zamacona, Miren; Dörner, Thomas; Urowitz, Murray; Hiepe, Falk (November 2017). "Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles". Annals of the Rheumatic Diseases. 76 (11): 1837–1844. doi:10.1136/annrheumdis-2017-211388. PMID 28780512. S2CID 3577398.
^ Askanase, A.; Stach, C.; Brittain, C.; Stojan, G.; Furie, R. (1 June 2023). "Pos0115 Dapirolizumab Pegol Efficacy by Subgroups in Patients with Systemic Lupus Erythematosus: A Post Hoc Analysis of Phase 2 Clinical Trial Data". Annals of the Rheumatic Diseases. 82 (Suppl 1): 272–273. doi:10.1136/annrheumdis-2023-eular.1991. ISSN 0003-4967. S2CID 259786801.
^ Furie, Richard A; Bruce, Ian N; Dörner, Thomas; Leon, Manuel Gustavo; Leszczyński, Piotr; Urowitz, Murray; Haier, Birgit; Jimenez, Teri; Brittain, Claire; Liu, Jiajun; Barbey, Catherine; Stach, Christian (6 May 2021). "Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol inpatients with moderate-to-severe active systemic lupus erythematosus". Rheumatology. 60 (11): 5397–5407. doi:10.1093/rheumatology/keab381. ISSN 1462-0324. PMC 9194804. PMID 33956056.